QuantifiCare, a global leader in imaging solutions, announces a a significant first-instance decision before the Unified Patent Court (UPC), Düsseldorf Local Division. In its decision of April 23, 2026, the UPC ruled in favor of QuantifiCare in its infringement action concerning European Patent EP 3 156 843, covering innovative technology for three-dimensional reconstruction of the head and body.
The Court dismissed the defendants’ counterclaim for invalidity in its entirety and confirmed the validity of QuantifiCare’s patent. It further found that the Canfield’s Vectra H2 system infringes the patent and granted broad relief for Belgium, France, Italy, and the Netherlands. This is a first-instance judgment and may be subject to appeal.
The decision notably provides for a multi-country injunction, recall and removal of infringing products, disclosure obligations, as well as provisional damages and cost reimbursement in favor of QuantifiCare.
Importantly, the Court confirmed that a single act of infringement in one UPC member state can justify remedies across all countries where the patent is in force, , even if an infringing act can only be determined in a contracting member state in which the patent proprietor does not assert any claims in the infringement action for procedural reasons: In the present case, as QuantifiCare has already taken action against Canfield in national court proceedings in Germany, Germany has effectively been carved out. This clarification strengthens the UPC’s role as a powerful forum for pan-European patent enforcement.
“This decision is a major milestone for QuantifiCare and a strong validation of the robustness of our intellectual property” said Jean-Philippe THIRION, QuantifiCare’s CEO. “It reinforces our commitment to innovation in medical imaging and to protecting the technologies that support better clinical outcomes worldwide.”
Founded in France, QuantifiCare develops cutting-edge imaging systems and software used in clinical trials, dermatology, and aesthetic medicine. Its solutions enable precise, reproducible, and quantitative analysis of skin and anatomical structures, supporting pharmaceutical companies and healthcare professionals in the development and evaluation of new treatments.
About LifeViz® Infinity:
The LifeViz® Infinity is a portable, all-in-one 3D imaging system designed for the face, breast, and body in medical, aesthetic and clinical trials. This groundbreaking device features a dual-distance repositioning system tailored for different imaging needs: one distance optimized for facial imaging and the other for breast and body imaging. The system utilizes two pairs of light beamers – crossing red beamers for short-distance (face) imaging and green beamers for long-distance (breast and body) imaging. Additionally, it includes a convenient switch to select the appropriate distance and adapt imaging accordingly. The LifeViz® Infinity is marketed internationally by its parent company’s subsidiary, Quartier Latin.
Link to the press:
For further information, please contact:
info@quantificare.com
info.hq@qlatin.com
